Literature DB >> 33363011

Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer.

Peng-Ju Gong1, You-Cheng Shao2, Yan Yang1, Wen-Jing Song1, Xin He1, Yi-Fan Zeng1, Si-Rui Huang1, Lei Wei2, Jing-Wei Zhang1.   

Abstract

OBJECTIVES: Recently, an increasing number of studies have revealed that N6-methyladenosine (m6A) functions as a significant post-transcriptional modification which plays a critical role in the occurrence and progression of enriched tumors by regulating coding and non-coding RNA biogenesis. However, the biological function of m6A in breast cancer remains largely unclear.
MATERIALS AND METHODS: In this study, we used a series of bioinformatic databases and tools to jointly analyze the expression of m6A methylation transferases (METTL3, METTL14, WTAP, RBM15, RBM15B and ZC3H13) and investigate the prognostic value of METTL14 and ZC3H13 in breast cancer. Besides, we analyzed the downstream carcinogenic molecular mechanisms related to METTL14 and ZC3H13 and their relationship with immune infiltration in breast tumor tissues.
RESULTS: The results showed that METTL14 and ZC3H13 were the down-regulated m6A methylation transferases in breast cancer. Survival outcome analysis suggested that abnormally low expression of METTL14 and ZC3H13 could predict unfavorable prognosis in four breast cancer subtypes. Moreover, their down-regulation was associated with ER-, PR- and triple-negative breast cancer patients, as well as tumor progression (increased Scarff, Bloom and Richardson grade status and Nottingham Prognostic Index classification). Co-expression analysis revealed that METTL14 and ZC3H13 had a strong positive correlation with APC, an antagonist of the Wnt signaling pathway, indicating they might cooperate in regulating proliferation, invasion, and metastasis of tumor cells. METTL14, ZC3H13, and APC expression levels had significant positive correlation with infiltrating levels of CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells, and negative correlation with Treg cells in breast cancer.
CONCLUSIONS: This study demonstrated that down-regulation of METTL14 and ZC3H13 which act as two tumor suppressor genes was found in breast cancer and predicted poor prognosis. Their abnormal expression promoted breast cancer invasion by affecting pathways related to tumor progression and mediating immunosuppression.
Copyright © 2020 Gong, Shao, Yang, Song, He, Zeng, Huang, Wei and Zhang.

Entities:  

Keywords:  APC; METTL14; Wnt signaling pathway; ZC3H13; breast cancer; m6A; prognosis

Year:  2020        PMID: 33363011      PMCID: PMC7757663          DOI: 10.3389/fonc.2020.578963

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  51 in total

Review 1.  Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.

Authors:  Yoshie Kobayashi; Seung-Oe Lim; Hirohito Yamaguchi
Journal:  Semin Cancer Biol       Date:  2019-12-23       Impact factor: 15.707

Review 2.  Precision medicine for metastatic breast cancer--limitations and solutions.

Authors:  Monica Arnedos; Cecile Vicier; Sherene Loi; Celine Lefebvre; Stefan Michiels; Herve Bonnefoi; Fabrice Andre
Journal:  Nat Rev Clin Oncol       Date:  2015-07-21       Impact factor: 66.675

Review 3.  The Wnt signaling pathway: a potential therapeutic target against cancer.

Authors:  Noyel Ghosh; Uday Hossain; Ankita Mandal; Parames C Sil
Journal:  Ann N Y Acad Sci       Date:  2019-04-24       Impact factor: 5.691

4.  Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells.

Authors:  R Desrosiers; K Friderici; F Rottman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

Review 5.  Role of RNA modifications in cancer.

Authors:  Isaia Barbieri; Tony Kouzarides
Journal:  Nat Rev Cancer       Date:  2020-04-16       Impact factor: 60.716

6.  Cytoscape 2.8: new features for data integration and network visualization.

Authors:  Michael E Smoot; Keiichiro Ono; Johannes Ruscheinski; Peng-Liang Wang; Trey Ideker
Journal:  Bioinformatics       Date:  2010-12-12       Impact factor: 6.937

7.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.

Authors:  Zefang Tang; Chenwei Li; Boxi Kang; Ge Gao; Cheng Li; Zemin Zhang
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

8.  WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.

Authors:  Yunhao Chen; Chuanhui Peng; Junru Chen; Diyu Chen; Beng Yang; Bin He; Wendi Hu; Yanpeng Zhang; Hua Liu; Longfei Dai; Haiyang Xie; Lin Zhou; Jian Wu; Shusen Zheng
Journal:  Mol Cancer       Date:  2019-08-22       Impact factor: 27.401

9.  METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.

Authors:  Ben Yue; Chenlong Song; Linxi Yang; Ran Cui; Xingwang Cheng; Zizhen Zhang; Gang Zhao
Journal:  Mol Cancer       Date:  2019-10-13       Impact factor: 27.401

10.  STRING v9.1: protein-protein interaction networks, with increased coverage and integration.

Authors:  Andrea Franceschini; Damian Szklarczyk; Sune Frankild; Michael Kuhn; Milan Simonovic; Alexander Roth; Jianyi Lin; Pablo Minguez; Peer Bork; Christian von Mering; Lars J Jensen
Journal:  Nucleic Acids Res       Date:  2012-11-29       Impact factor: 16.971

View more
  23 in total

Review 1.  The Key Role of RNA Modification in Breast Cancer.

Authors:  Yang Liu; Tong Zhu; Yi Jiang; Jiawen Bu; Xudong Zhu; Xi Gu
Journal:  Front Cell Dev Biol       Date:  2022-06-01

Review 2.  Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application.

Authors:  Fusheng Zhang; Haiyang Liu; Meiqi Duan; Guang Wang; Zhenghou Zhang; Yutian Wang; Yiping Qian; Zhi Yang; Xiaofeng Jiang
Journal:  J Hematol Oncol       Date:  2022-07-06       Impact factor: 23.168

3.  Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer.

Authors:  Yang Yang; Zhouyao Qian; Mingyang Feng; Weiting Liao; Qiuji Wu; Feng Wen; Qiu Li
Journal:  BMC Bioinformatics       Date:  2022-10-19       Impact factor: 3.307

Review 4.  Role of m6A in osteoporosis, arthritis and osteosarcoma (Review).

Authors:  Yibo Hu; Xiaohui Zhao
Journal:  Exp Ther Med       Date:  2021-06-30       Impact factor: 2.447

Review 5.  The Interaction Between N6-Methyladenosine Modification and Non-Coding RNAs in Gastrointestinal Tract Cancers.

Authors:  Lin Yao; Chang-Feng Man; Rong He; Lian He; Jia-Bin Huang; Shou-Yan Xiang; Zhe Dai; Xiao-Yan Wang; Yu Fan
Journal:  Front Oncol       Date:  2022-01-07       Impact factor: 6.244

6.  Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells.

Authors:  Ning Zhang; Xiaohui Hua; Huailu Tu; Jingxia Li; Zhuo Zhang; Costa Max
Journal:  Cancer Lett       Date:  2021-07-28       Impact factor: 9.756

Review 7.  The Role of N6-Methyladenosine (m6A) Methylation Modifications in Hematological Malignancies.

Authors:  Yan Zhao; Hongling Peng
Journal:  Cancers (Basel)       Date:  2022-01-11       Impact factor: 6.639

8.  The Role of m6A RNA Methylation-Related lncRNAs in the Prognosis and Tumor Immune Microenvironment of Papillary Thyroid Carcinoma.

Authors:  Wenlong Wang; Cong Shen; Yunzhe Zhao; Botao Sun; Xiangyuan Qiu; Shujuan Yin; Jiaxin Chen; Xinying Li
Journal:  Front Cell Dev Biol       Date:  2022-01-03

9.  Analysis and validation of m6A regulatory network: a novel circBACH2/has-miR-944/HNRNPC axis in breast cancer progression.

Authors:  Wenchang Lv; Yufang Tan; Mingchen Xiong; Chongru Zhao; Yichen Wang; Min Wu; Yiping Wu; Qi Zhang
Journal:  J Transl Med       Date:  2021-12-24       Impact factor: 5.531

10.  N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer.

Authors:  Yanni Song; Chaojing Zheng; Yangbao Tao; Rui Huang; Qian Zhang
Journal:  Med Sci Monit       Date:  2021-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.